Syncom Formulations: consolidated PAT up 60.6% YoY on margin expansion, revenue +16.8%
PAT +60.55% YoY · revenue +16.78% · margins expanding
₹142.14 Cr
+16.78% YoY
₹26.65 Cr
+60.55% YoY
17.98%
+4.9pp YoY
₹0.28
Syncom Formulations' consolidated profit after tax rose 60.6% year-on-year to ₹26.65 Cr in Q2 FY27 (₹16.60 Cr in Q2 FY26), comfortably outpacing the 16.8% YoY rise in consolidated revenue from operations to ₹142.14 Cr (₹121.72 Cr). The gap is almost entirely margin-driven: consolidated net profit margin expanded to roughly 18.0% of total income from 13.08% a year ago, continuing the trend through FY27 (operating margin, per company records, moved from 15.12% in Q2 FY26 to 20.88% in Q1 FY27). Sequentially growth is more moderate — revenue rose 13.2% and PAT 7.3% over Q1 FY27's ₹125.53 Cr and ₹24.85 Cr — and NPM eased slightly from Q1's 18.63%, suggesting the pace of margin gains is flattening even as the YoY base effect stays favourable. Standalone PAT grew a slower 50.8% YoY to ₹25.40 Cr on 12.5% YoY revenue growth, a gap of roughly 10 percentage points versus the consolidated PAT growth rate — the three wholly-owned subsidiaries (Sante Biotech, Synmex Pharma, Vincit Biotech International) are contributing a modestly larger share of profit than a year ago. Neither statement carries any exceptional item in the current or year-ago quarter, so the swing is organic and operating in nature, visible mainly in cost of materials consumed growing slower than revenue at the consolidated level.
Q2 FY-2027 vs prior quarters
There is no prior management guidance or concall commentary on record for this company, and with zero analysts covering the stock (per SimplyWall St/TipRanks screens), there is no street consensus to measure the print against — both angles resolve to "unknown" rather than a silent gap. No press release accompanied this filing, so there is no management framing to reconcile against the numbers. The quarter's corporate actions sit alongside, not inside, the P&L: the board approved a ₹0.10-per-share final dividend and promoters voluntarily forwent ₹4.75 Cr of dividend entitlement in late September, and a new Managing Director and Whole-Time Director was appointed effective October 1, 2026 — after this reporting period closed, so any operating impact first shows up in Q3 FY27. The 38th AGM concluded on September 30 with e-voting results pending at filing time. Going into Q3, the open question is whether the margin expansion seen across the first two quarters of FY27 continues or plateaus, given this quarter's NPM already stepped down slightly from Q1's level.
The stock went into the print at ₹20.29, down 9.6% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; revenue is at a 6-quarter high.
What the summary numbers don't show
Consolidated basic EPS ₹0.28 for the quarter, up from ₹0.18 YoY and ₹0.26 QoQ.
W1
No formal guidance on record — next checkpoint is whether Q3 FY27 sustains the YoY margin expansion (consolidated NPM 13.08% → ~18.0% over the past four quarters) or the sequential plateau seen this quarter (18.63% → ~18.0%) continues.
W2
New Managing Director & Whole-Time Director took charge October 1, 2026, just after quarter-end — watch Q3 FY27 results/commentary for any shift in operating trends under the new leadership.
W3
Consolidated vs standalone PAT growth gap (60.6% vs 50.8% YoY) — watch whether subsidiary (Sante Biotech, Synmex Pharma, Vincit Biotech International) contribution keeps widening or converges.
Clean, legible filing with unambiguous column headers for 30/09/2026; both standalone and consolidated statements present with exact arithmetic tie-outs (PBT-tax=PAT, revenue+other income=total income); no exceptional items in the quarterly column for either basis; figures converted from ₹ Lakhs to ₹ Crore.